Improved Tumor Targeting with Chemically Cross-Linked Recombinant Antibody Fragments

Cancer Research

Volumn 54, Issue 23, 1994, Pages 6176-6185

  Shochat, Dan ^c   Pedley, R Barbara ^b   Farnsworth, Andrew P H ^a   Adair, John R ^a   Baldock, Darren ^a   Proudfoot, Karen A ^a   Lawson, Alastair D G ^a   Beeley, Nigel R A ^a   Millar, Kenny ^a   Millican, T Andrew ^a   Boyce, Byron A ^a   Antoniw, Pari ^a   Mountain, Andrew ^a   Regent, Richard H J ^a   Yarranton, Geoffrey T ^a  

^a UCB PHARMA   (Belgium)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CHIMERA; CHO CELL; GENE TARGETING; HALF LIFE TIME; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RADIOISOTOPE THERAPY;

ANIMALS; CATTLE; CHO CELLS; CRICETINAE; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FRAGMENTS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RADIOIMMUNOTHERAPY; RECOMBINANT PROTEINS; TRANSPLANTATION, HETEROLOGOUS; YTTRIUM RADIOISOTOPES;

EID: 0028091566     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Goldenberg, D.M. Sharkey, R.M. Blumenthal, R.D. Goldenberg, H. Murthy, S. Hansen, H.J. and Pinsky, C.M. Problems and prospects for radioimmunodetection and radioimmunotherapy of cancer. Antibody Immunoconj. Radiopharmacol. 3: 151-167, 1990.
2. Mach, J.P. Pelegrin, A. and Buchegger, F. Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors. Curr. Opin. Immunol. 3: 685-693, 1991.
3. Mountain, A. and Adair, J.R. Engineering antibodies for therapy. In: M. P Tombs (ed.), Biotechnology and Genetic Engineering Reviews, Vol. 10, pp. 1-142. Andover, UK: Intercept, 1992.
4. Khazaeli, M.B. Saleh, M.N. Liu, T.P. Meredith, R.F. Wheeler, R.H. Baker, T.S. King, D. Secher, D.S. Allen, L. Rogers, K. Colcher, D. Schlom, J. Shochat, D. and LoBuglio, A.F. Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human γ4) monoclonal antibody in humans. Cancer Res. 51: 5461-5466, 1991.
5. Meredith, R.F. Khazaeli, M.B. Grizzle, W.E. Orr, R.A. Plott, G. Urist, M.M. Liu, T. Russell, C.D. Wheeler, R.H. Schlom, J. and LoBuglio, A.F. Direct localisation comparison of murine and chimeric B72.3 antibodies in patients with colon cancer. Hum. Antib. Hybrid. 4: 190-197, 1993.
6. Ong, G.L. Ettenson, D. Sharkey, R.M. Marks, A. Baumal, R. Goldenberg, D.M. and Mattes, M.J. Galactose conjugated antibodies in cancer therapy: properties and principles of action. Cancer Res. 51: 1619-1626, 1991.
7. Begent, R.H.J. Bagshawe, K D. Pedley, R.B. Searle, F. Ledermann, J.A. Green, A.J. Keep, P.A. Chester, K.A. Glaser, M.G. and Dale, R.G. Use of second antibody in radioimmunotherapy. Natl. Cancer Inst. Monogr. 3: 59-61, 1987.
8. Goldenberg, D.M. Sharkey, R.M. and Ford, E. Anti-antibody enhancement of iodine-131 anti-CEA radioimmunodetection in experimental and clinical studies. J. Nucl. Med. 28: 1604-1610, 1987.
9. Johnson, T.K. Maddock, S. Ksaliwal, R. Bloedow, D. Hartmann, C. Feyerabend, A. Dienhart, D.G. Thickman, D. Glenn, S. Gonzalez, R. Lear, J. and Bunn, P. Radioimmunoadsorption of KC-4G3 antibody in peripheral blood: implications for radioimmunotherapy. Antibod. Immunoconj. Radiopharmacol. 4: 885-893, 1991.
10. Norrgren, K. Strand, S.E. Nilsson, R. Lindgren, L. and Sjogren, H.O. A general, extracorporeal method to increase the tumor-to-normal tissue ratio in radioimmuno-imaging and radioimmunotherapy. J. Nucl. Med. 34: 448-454, 1993.
11. Brown, B.A. Dearborn, C.B. Drozynski, C.A. and Sands, H. Pharmacokinetics of 99mTc-metallothionein-B72.3 and its F(ab’)2 fragment. Cancer Res. 50 (Suppl.): 835s-839s, 1990.
12. Milenic, D.E. Yokota, T. Filipula, D.R. Finkelman, M.A.J. Dodd, S.W. Wood, J.F. Whitlow, M. Snoy, P. and Schlom, J. Construction, binding properties, metabolism and tumor targeting of a single chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 51: 6363-6371, 1991.
13. Buchegger, F. Pelegrin, A. Delaloye, B. Bischoff-Delaloye, A. and Mach, J.P. Iodine-131 labelled Mab F(ab’)2 fragments are more effective and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J. Nucl. Med. 31: 1035-1044, 1990.
14. King, D.J. Mountain, A. Adair, J.R. Owens, R.J. Harvey, A. Weir, N. Proudfoot, K.A. Phipps, A. Lawson, A. Rhind, S.K. Pedley, B. Boden, J. Boden, R. Begent, R.H.J. and Yarranton, G.T. Tumor localization of engineered antibody fragments. Antibody Immunoconj. Radiopharmacol. 5: 159-170, 1992.
15. Brown, B.A. Comeau, R.D. Jones, P.L. Liberatore, F.A. Neacy, W.P. Sands, H. and Gallagher, B.M. Pharmacokinetics of the monoclonal antibody B72.3 and its fragments labelled with either 125I or 111In. Cancer Res. 47: 1149-1154, 1987.
16. Vogel, C A. Bischoff-Delaloye, A. Mach, J.P. Pelegrin, A. Hardman, N. Delaloye, B. and Buchegger, F. Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab’)2 fragment in nude mice bearing different human colon cancer xenografts. Br. J. Cancer, 68: 684-690, 1993.
17. Buist, M.R. Kenemans, P. den Hollander, W. Vermorken, J.B. Molthoff, C.J.M. Burger, C.W. Helmerhorst, T.J.M. Baak, J.P.A. and Roos, J.C. Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOvl8 IgG and F(ab’)2 fragments in ovarian cancer patients. Cancer Res. 53: 5413-5418, 1993.
18. Yorke, E.D. Beaumier, P.L. Wessels, B.W. Fritzberg, A.R. and Morgan, A.C. Jr. Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics. Nucl. Med. Biol. 18: 827-835, 1991.
19. Skerra, A. and Pluckthun, A. Assembly of a functional immunoglobulin Fv fragment in E. coli. Science (Washington DC), 240: 1038-1041, 1988.
20. Bird, R.E. Hardman, K.D. Jacobson, J.W. Johnson, S. Kaufman, B.M. Lee, S.M. Lee, T. Pope, S.H. Riordan, G.S. and Whitlow, M. Single-chain antigen-binding proteins. Science (Washington DC), 242: 423-426, 1988.
21. Huston, J.S. Levinson, D. Mudgett-Hunter, M. Tai, M.S. Novotoy, J. Margolies, M.N. Ridge, R.J. Bruccoleri, R.E. Haber, E. Crea, R. and Oppermann, H. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in E. coli. Proc. Natl. Acad. Sci. USA, 85: 5879-5883, 1988.
22. Better, M. Chang, P. Robinson, R.R. and Horwitz, A.H. Escherichia coli secretion of an active chimeric antibody fragment. Science (Washington DC), 240: 1041-1043, 1988.
23. King, D.J. Adair, J.R. Angal, S. Low, D.C. Proudfoot, K.A. Lloyd, J.C. Bodmer, M. and Yarranton, G.T. Expression, purification and characterization of a mouse: human chimeric antibody and chimeric Fab’ fragment. Biochem. J. 281: 317-323, 1992.
24. Carter, P. Kelley, R.F. Rodrigues, M.L. Snedcor, B. Covarrubias, M. Velligan, M.D. Wong, W.L.T. Rowland, A.M. Kotts, C.E. Carver, M.E. Yang, M. Bourell, J.H. Shepard, H.M. and Henner, D. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology, 10: 163-167, 1992.
25. Whittle, N.R. Adair, J.R. Lloyd, J.C. Jenkins, E. Devine, J. Schlom, J. Raubitschek, A. Colcher, D. and Bodmer M. Expression in COS cells of a mouse: human chimaeric B72.3 antibody. Protein Eng. 1: 499-505, 1987.
26. Bebbington, C.R. Expression of antibody genes in nonlymphoid mammalian cells. Methods (Orlando), 2: 136-145, 1992.
27. Desplancq, D. King, D.J. Lawson, A.D.G. and Mountain, A. Single chain Fv variants of the tumour-binding antibody B72.3. Protein Eng. 7: 1027-1033, 1994.
28. King, D.J. Byron, O.D. Mountain, A. Weir, N. Harvey, A. Lawson, A.D.G. Proudfoot, K.A. Baldock, D. Harding, S.E. Yarranton, G.T. and Owens, R.J. Expression, purification and characterization of B72.3 Fv fragments. Biochem. J. 290: 723-729, 1993.
29. Cox, J.P. Jankowski, K.J. Kataky, R. Parker, D. Beeley, N.R.A. Boyce, B.A. Eaton, M.A.W. Millar, K. Millican, A.T. Harrison, A. and Walker, C. Synthesis of a kinetically stable yttrium-90 labelled macrocycle-antibody conjugate. J. Chem. Soc. Chem. Commun. 1989: 797-798, 1989.
30. Harrison, A. Walker, C.A. Parker, D. Jankowski, K.J. Cox, J.P.L. Craig, A.S. Sansom, J.M. Beeley, N.R.A. Boyce, R.A. Chaplin, L. Eaton, M.A.W. Farnsworth, A.P.H. Millar, K. Millican, T.A. Randall, A.M. Rhind, S.K. Secher, D.S. and Turner, A. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates. Nucl. Med. Biol. 78: 469-476, 1991.
31. Schott, M.E. Frazier, K.A. Pollock, D.K. and Verbanac, K.M. Preparation, characterization and in vivo biodistribution properties of synthetically cross-linked multivalent antitumour antibody fragments. Bioconjugate Chem. 4: 153-165, 1993.
32. Sharkey, R.M. Motta-Hennessy, C. Pawlyk, D. Siegal, J.A. and Goldenberg, D.M. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 50: 2330-2336, 1990.
33. Schott, M.E. Milenic, D.E. Yokota, T. Whitlow, M. Wood, J.F. Fordyce, W.A. Cheng, R.C. and Schlom, J. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. Cancer Res. 52: 6413-6417, 1992.
34. Angal, S. King, D.J. Bodmer, M. Turner, A. Lawson, A.D.G. Roberts, G. Pedley, R.B. and Adair, J. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol. Immunol. 30: 105-108, 1993.
35. Scheinberg, D.A. Current applications of monoclonal antibodies for the therapy of hematopoietic cancers. Curr. Opin. Immunol. 3: 679-684, 1991.
36. Pedley, R.B. Boden, J. Boden, R. Dale, R. and Begent, R.H.J. Comparative radioimmunotherapy using intact or F(ab’)2 fragments of 131I anti-CEA antibody in a colonic xenograft model. Br. J. Cancer, 68: 69-73, 1993.
37. Hnatowich, D.J. Chinol, M. Siebacker, D.A. Gionet, M. Griffin, T. Doherty, P.W. Hunter, R. and Kase, K.R. Patient biodistribution of intraperitoneally administered Yttrium-90 labelled antibody. J. Nucl. Med. 29: 1428-1434, 1988.
38. Washburn, L.C. Yu-Chen, C. Tan, H.S. Byrd, B. Crook, J.E. Stabin, M.G. and Steplewski, Z. Preclinical assessment of 90Y-labelled monoclonal antibody C017-1A, a potential agent for radioimmunotherapy of colorectal carcinoma. Nucl. Med. Biol. 15: 707-711, 1988.
39. Kosmas, K. Snook, D. Gooden, C.S. Courtenay-Luck, N.J. McCall, M.J. Meares, C. and Epenetos, A.A. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunocon-jugates for imaging and therapy. Cancer Res. 52: 904-911, 1992.
40. Maack, T. Johnson, V. Kau, S.T. Figueiredo, J. and Sigulem, D. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 16: 251-270 1979.
41. Rodrigues, M.L. Snedcor, B. Chen, C. Wong, W.L.T. Garg, S. Blank, G.S. Maneval, D. and Carter, P. Engineering Fab’ fragments for efficient F(ab)2 formation in Escherichia coli and for improved in vivo stability. J. Immunol. 151: 6954-6961, 1993.
42. Glennie, M.J. McBride, H.M. Worth, A.T. and Stevenson, G.T. Preparation and performance of bispecific F(ab'γ)2 antibody containing thioether-linked Fab'γ fragments. J. Immunol. 139: 2367-2375, 1987.
43. Rodrigues, M.L. Shalaby, M.R. Werther, W. Presta, L. and Carter, P. Engineering a humanized bispecific F(ab’)2 fragment for improved binding to T cells. Int. J. Cancer 7 (Suppl.): 45-50, 1992.
44. Quadri, S.M. Lai, J. Mohammadpor, H. Vriesendorp, H.M. and Williams, J.R. Assessment of radiolabelled stabilized F(ab’)2 fragments of monoclonal antiferritin in nude mouse model. J. Nucl. Med. 34: 2152-2159, 1993.
45. Tutt, A. Greenman, J. Stevenson, G.T. and Glennie, M.J. Bispecific F(ab'γ)3 antibody derivatives for redirecting unprimed cytotoxic T cells. Eur. J. Immunol. 21: 1351-1358, 1991.
46. Tutt, A. Stevenson, G.T. and Glennie, M.J. Trispecific F(ab’)3 derivatives that use cooperative signalling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells. J. Immunol. 147: 60-69, 1991.
47. Adams, G.P. McCartney, J.E. Tai, M.S. Oppermann, H. Huston, J.S. Stafford, W.F. III, Bookman, M.A. Fand, I. Houston, L.L. and Weiner, L.M. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-erbB2 single-chain Fv. Cancer Res. 53: 4026-4034, 1993.
48. Cumber, A.J. Ward, E.S. Winter, G. Parnell, G.D. and Warwrznczak, E.J. Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate. J. Immunol. 149: 120-126, 1992.
49. Owens, R.J. King, D.J. Howat, D. Lisle, H. Mountain, A. Harvey, A. Bergin, S. Turner, A. Pedley, B. Boden, J. Begent, R. and Yarranton, G.T. Tumor binding properties of B72.3 Fv fragments. Antibody Immunoconj. Radiopharmacol. 4: 459-467, 1991.
50. Yokota, T. Milenic, D.E. Whitlow, M. and Schlom, J. Rapid tumor penetration of a single chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52: 3402-3408, 1992.